55 completed, 9 withdrawn, 5 terminated, 3 recruiting. 25 Phase 3, 23 Phase 4, 12 Not applicable, 10 Phase 2, 7 Phase 1.
Follow Conjunctivitis, Bacterial: new trials by email Literature Review of Conjunctivitis, Bacterial trials Research Report on Conjunctivitis, Bacterial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Impact of Oral Ivermectin on Musca Sorbens Flies, Putative Vector of Trachoma Ivermectin - Survival of Flies Developing in Faecal Samples | Phase 4 | Not yet recruiting | London School of Hygiene and Tropical Medicine | 12 | 2026-10-05 | 2026-10-30 |
| Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis SUM-191, Placebo - Bacterial Conjunctivitis | Phase 1 / Phase 2 | Recruiting | Senju USA, Inc. | 426 | 2026-06-25 | 2026-06-30 |
| RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs) B-RAP, BLTR - Trachoma, Eye Diseases | Not applicable | Recruiting | University of North Carolina, Chapel Hill | 1000 | 2026-01-13 | 2026-04-13 |
| Trachoma Elimination Study by Focused Antibiotic (TESFA) Azithromycin mass treatment, Azithromycin targeted treatment - Trachoma | Phase 4 | Withdrawn | Emory University | 2025-06-01 | 2025-07-16 | |
| Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis Fusidic Acid 1%, Placebo - Bacterial Conjunctivitis | Phase 3 | Recruiting | Baxis Pharmaceuticals, Inc. | 400 | 2025-03-21 | 2026-03-17 |
| Azithromycin Reduction to Reach Elimination of Trachoma B Azithromycin - Trachoma | Phase 4 | Withdrawn | University of California, San Francisco | 2024-10-01 | 2026-03-13 | |
| Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects PRO-231, VIGAMOXI® - Ophthalmological Agent Toxicity, Bacterial Conjunctivitis | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 37 | 2024-01-30 | 2025-06-15 |
| Enhancing the A in SAFE for Trachoma Azithromycin for Routine Community-wide MDA, Two Additional Rounds of Azithromycin for Children, Azithromycin for Second Community-wide MDA - Trachoma | Phase 4 | Completed | Emory University | 34630 | 2022-05-04 | 2024-02-29 |
| Kebele Elimination of Trachoma for Ocular Health Azithromycin - Trachoma | Phase 4 | Active not recruiting | University of California, San Francisco | 320000 | 2022-02-07 | 2025-10-23 |
| Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin Administration of Albendazole on Day 1, Administration of Ivermectin on Day 1, Administration of Azithromycin on Day 1 - Trachoma, Lymphatic Filariases | Phase 4 | Completed | London School of Hygiene and Tropical Medicine | 13511 | 2021-12-01 | 2022-08-19 |
| Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults RD03/2016 eye drops, Levofloxacin 0.5% eye drops solution (Oftaquix®) - Conjunctivitis, Bacterial | Phase 2 | Completed | NTC srl | 252 | 2021-11-05 | 2024-09-27 |
| Azithromycin Reduction to Reach Elimination of Trachoma Azithromycin - Trachoma | Phase 4 | Completed | University of California, San Francisco | 3931 | 2021-05-29 | 2026-03-25 |
| Safety and Immunogenicity of a Chlamydia Vaccine CTH522 CTH522-CAF01 IM, CTH522-CAF09b IM, CTH522 ID - Trachoma | Phase 1 | Completed | Statens Serum Institut | 65 | 2020-02-17 | 2024-08-22 |
| Smartphone App for Taking Images of Conjunctivae TOFTEE - Trachoma | Not applicable | Terminated | London School of Hygiene and Tropical Medicine | 125 | 2019-07-08 | 2022-08-22 |
| App-based Versus Slide-based Inter-grader Agreement (IGA) Test for Trachoma Graders Inter-grader agreement (IGA) app - Trachoma | Not applicable | Terminated | London School of Hygiene and Tropical Medicine | 32 | 2019-07-08 | 2022-08-22 |
| Microbiologic Alterations of the Conjunctiva of Hot Tub-soaking Ophthalmologists Dunk, Exposure to Hot Tub - Conjunctivitis, Bacterial, Keratitis Bacterial | Not applicable | Completed | University of California, San Francisco | 36 | 2019-05-27 | 2020-09-10 |
| Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma IR3535, Permethrin lower dose, Permethrin higher dose - Trachoma | Phase 2 | Completed | London School of Hygiene and Tropical Medicine | 64 | 2019-01-10 | 2020-04-08 |
| Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Albendazole on Day 1, Ivermectin on Day 1, Diethylcarbamazine on day 1 - Trachoma, Yaws | Phase 3 | Completed | Lihir Medical Centre | 20000 | 2018-10-01 | 2019-02-28 |
| Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. Pazufloxacin, Zymar - Conjunctivitis, Bacterial | Phase 3 | Terminated | Laboratorios Sophia S.A de C.V. | 46 | 2018-10-01 | 2021-08-24 |
| Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects PRO-174, Sophixín Ofteno® - Conjunctivitis, Conjunctivitis, Bacterial | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 30 | 2018-01-25 | 2019-10-25 |
Showing 20 of 76. Sign in to see all of them.
Trachoma (38) · Chlamydia Infections (7) · Conjunctivitis (7) · Trichiasis (6) · Bacterial Infections (5) · Elephantiasis, Filarial (4) · Eye Diseases (4) · Eye Infections (3) · Infections (3) · Eye Infections, Bacterial (2) · Keratitis (2) · Neglected Diseases (2) · Ophthalmia Neonatorum (2) · Amblyopia (1)
Bacterial Infections and Mycoses (76) · Conjunctival Diseases (75) · Eye Infections, Bacterial (74) · Eye Infections (73) · Infections (73) · Eye Diseases (72) · Bacterial Infections (71) · Conjunctivitis (69) · Gram-Negative Bacterial Infections (41) · Chlamydiaceae Infections (40) · Corneal Diseases (39) · Chlamydia Infections (33) · Communicable Diseases (7) · Eyelid Diseases (7)
Azithromycin (24) · Gatifloxacin (6) · Moxifloxacin (6) · Ophthalmic Solutions (6) · besifloxacin (6) · Ivermectin (4) · Albendazole (3) · Permethrin (2) · Water (2) · pazufloxacin (2) · Alkalies (1) · Amoxicillin (1) · Amyloid (1) · Diethylcarbamazine (1) · Educational Status (1)
University of California, San Francisco (14) · Alcon Research (7) · Johns Hopkins University (7) · London School of Hygiene and Tropical Medicine (7) · Bausch & Lomb Incorporated (6) · Laboratorios Sophia S.A de C.V. (5) · Allergan (3) · Emory University (3) · Laboratoires Thea (2) · Merck Sharp & Dohme LLC (2) · Adapt Produtos Oftalmológicos Ltda. (1) · Azidus Brasil (1) · Baskent University (1) · Baxis Pharmaceuticals, Inc. (1) · Beijing Tongren Hospital (1)
United States (33) · Ethiopia (11) · Mexico (5) · Tanzania (5) · United Kingdom (5) · Niger (3) · Brazil (2) · Canada (2) · China (2) · France (2) · Italy (2) · Poland (2) · Spain (2) · Australia (1) · Austria (1)
Tom Lietman, MD (3) · Catherine Oldenburg, ScD, MPH (2) · Elodie Lebas, RN (2) · Emily Gower, PhD (2) · Emma Harding-Esch (2) · Jeremy D Keenan, MD, MPH (2) · Johnson Varughese (2) · Julius Schachter, PhD (2) · Kieran S O'Brien, MPH (2) · Matthew J Burton, PhD FRCOphth (2) · Paul Emerson, PhD (2) · Sheila K West (2)
PMID 31589610, PMID 21681652, PMID 22953007, PMID 16905024, PMID 17583820, PMID 17652708, PMID 18374301, PMID 19329003, PMID 19393842, PMID 20629472, PMID 21072224, PMID 21397770, PMID 21685340, PMID 22095569, PMID 22180731, PMID 22180732, PMID 22192488, PMID 22420526, PMID 22545165, PMID 22644963, PMID 22736616, PMID 23326612, PMID 23392481, PMID 23494035, PMID 23675549, PMID 23785525, PMID 24433194, PMID 24621121, PMID 25002297, PMID 25244402, PMID 25407464, PMID 25858004, PMID 26302380, PMID 26489933, PMID 27956455, PMID 28351345, PMID 28402408, PMID 28662043, PMID 28893761, PMID 29088030, PMID 29260659, PMID 29561511, PMID 29602567, PMID 29897440, PMID 30014828, PMID 30106956, PMID 30151409, PMID 30419040, PMID 30515431, PMID 30689671
5UG1EY030833 (2), R01AI048789 (2), 1UG1EY028088 (1), 1UG1EY036891 (1), 2016 (1), K23EY019881 (1), U10EY022584 (1), U10EY023939 (1)